Therapy via targeted delivery of nanoscale particles using L6 antibodies

• US 20040156846A1
• Filed: 02/06/2003
• Published: 08/12/2004
• Est. Priority Date: 02/06/2003
• Status: Abandoned Application

• Current Assignee: Triton Biosystems Inc (Novartis Ag)
• Original Assignee: Triton Biosystems Inc (Novartis Ag)
• Inventors: DeNardo, Gerald, Handy, Erik Schroeder, Foreman, Alan, Daum, Wolfgang, Ellis-Busby, Diane, Ivkov, Robert, Gwost, Douglas U.
• Application Number:
  US10/360,578
• Publication Number:
  US 20040156846A1
• Time in Patent Office: Days
• US Class Current: 424/144.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61N 2/002 in combination with another treatment
• CPC Class Codes: A61N 2/02 using magnetic fields produced by coils, including single turn loops or electromagnets A61N2/12 takes precedence
• CPC Class Codes: A61N 5/02 using microwaves
• CPC Class Codes: C07K 16/30 from tumour cells

Abstract

Methods for treating cells, diseased tissue, pathogens, or other undesirable matter involve the administration of a bioprobe (energy susceptive materials that are attached to the target-specific ligand chimeric L6 antibody) to a patient'"'"'s body, body part, tissue, or body fluid (such as blood, blood plasma, or blood serum). An energy source provides energy to the bioprobe so as to destroy, rupture, or inactivate the target. Various energy forms, such as AMF, microwave, acoustic, or a combination thereof, created via a variety of mechanisms, may be used. The disclosed methods may be useful in the treatment of a variety of indications, including but not limited to, cancer of any type, such as bone marrow, lung, vascular, neuro, colon, ovarian, breast and prostate cancer.

Claims

1. A therapeutic method, comprising:

a) administering at least one bioprobe to at least a portion of a subject comprising a target; and

b) administering energy from an energy source to the at least one bioprobe combined with the target; and

wherein the bioprobe comprises a susceptor and a chimeric L6 antibody.

2. A therapeutic method according to claim 1, wherein the target is associated with a cancer.

3. A therapeutic method according to claim 2, wherein the target comprises a marker and wherein the marker is a glycoprotein antigen.

4. A therapeutic method according to claim 3, wherein the marker glycoprotein is an L6 antigen.

5. A therapeutic method according to claim 1, wherein the chimeric antibody to marker L6 antigen comprises a human IgG1 constant region and a variable region of the mouse antibody to L6 antigen.

6. A therapeutic method according to claim 1, wherein the energy is administered to provide heating, and wherein the energy is in the form of AMF, microwave, acoustic, or any combination of thereof.

7. A therapeutic method according to claim 6, wherein the energy form is microwave having a frequency of at least 900 MHz, AMF having a frequency of from about 0.1 Hz to 900 MHz, acoustic having a frequency of from about 500 kHz to about 16 MHz, or any combination thereof.

8. A therapeutic method according to claim 6, wherein the energy is pulsed.

9. A therapeutic method according to claim 8, wherein the energy ‘

on’

pulse times are in the range from about 0.1 seconds to about 1200 seconds, and the ‘

off’

pulse times are in the range from about 0.1 seconds to about 1200 seconds.

10. A therapeutic method according to claim 1, wherein the energy source provides energy in a frequency range in which the susceptor possesses a resonance frequency, causing the energy absorption of the susceptor to be enhanced at said resonance frequency.

11. A therapeutic method according to claim 10, wherein the energy source is pulsed.

12. A therapeutic method according to claim 1, wherein the portion of the subject is extracted from the subject'"'"'s body prior to extracorporeal administration of energy.

13. A therapeutic method according to claim 12, wherein the extracted portion of the subject is returned to the subject'"'"'s body or is transplanted to a recipient'"'"'s body after the administration of energy.

14. A therapeutic method according to claim 12, wherein the extracted portion of the subject is cooled before, during or after the administration of energy.

15. A therapeutic method according to claim 14, wherein the susceptor is magnetic, and wherein the magnetic susceptor is removed from the extracted portion via a magnetic force after the administration of energy.

16. A therapeutic method according to claim 1, further comprising surgically opening the subject, and wherein the portion of the subject is tissue laid open to provide access for bringing the energy source close to the targeted tissue.

17. A therapeutic method according to claim 7, wherein the susceptor comprises a group of nitrogen-doped Mn clusters, MnN, Mn_xN, Mn-doped GaN, Nd_1-xCa_xFeO₃, superparamagnetic Co₃₆C₆₄, Bi₃Fe₅O₁₂, BaFe₁₂O₁₉, NiFe, CoNiFe, Co—

Fe₃O₄, FePt—

Ag, or a combination thereof, and wherein the susceptor is heated via AMF.

18. A therapeutic method according to claim 7, wherein the susceptor comprises a magnetic core having a gold coating, and wherein the energy is AMF heating.

20. A therapeutic method according to claim 7, wherein the energy is in the form of AMF and heats the bioprobe, and wherein the AMF further induces eddy current heating of the portion of the subject.

21. A therapeutic method according to claim 1, wherein the energy is administered to cause mechanical motion of the susceptor, and wherein the energy is in the form of acoustic energy.

22. A therapeutic method according to claim 21, wherein the susceptor is a nanotube fabricated from MoS₂, single crystal C₆₀, W₁₈O₄₉, NiCl₂, NbS₂, or GaSe, or a combination thereof.

23. A therapeutic method according to claim 21, wherein the acoustic energy has frequencies in the range from about 500 kHz to about 16 MHz.

19. A therapeutic method according to claim 19, wherein the susceptor comprises an organic thiol moiety that is attached to the gold coating, and wherein the bioprobe ligand is attached to the organic thiol moiety using at least one silane, carboxyl, amine, hydroxyl group or a combination thereof.